CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK3-IN-10
CAS:<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347DB18
CAS:<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Fórmula:C24H18ClN7O3Cor e Forma:SolidPeso molecular:487.9(R)-Atuveciclib
CAS:<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Fórmula:C18H18FN5O2SPureza:98%Cor e Forma:SolidPeso molecular:387.43CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SCor e Forma:SolidPeso molecular:437.52CDK2 degrader 6
CAS:<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Fórmula:C23H22F5N5O3Cor e Forma:SolidPeso molecular:511.44INX-315
CAS:<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Fórmula:C19H21N7O3SPureza:99.88%Cor e Forma:SolidPeso molecular:427.48CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Fórmula:C27H35N5O2Cor e Forma:SolidPeso molecular:461.6CDK8-IN-11 hydrochloride
<p>CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.</p>Fórmula:C19H16ClF3N4O2Cor e Forma:SolidPeso molecular:424.8CDK9-IN-38
CAS:<p>CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.</p>Fórmula:C22H23N5O3SCor e Forma:SolidPeso molecular:437.515CDK4/6-IN-13
CAS:<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Fórmula:C25H29N7OCor e Forma:SolidPeso molecular:443.54CLK1/4-IN-1
<p>CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.</p>Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81CDK4/6-IN-24
CAS:<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Fórmula:C32H41N7O3Cor e Forma:SolidPeso molecular:571.713Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47Cdc7-IN-11
CAS:<p>Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.</p>Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384CDK2-IN-30
CAS:<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Fórmula:C18H25N7O3SCor e Forma:SolidPeso molecular:419.50CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Fórmula:C21H22N4OCor e Forma:SolidPeso molecular:346.43CDDD11-8
CAS:<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Fórmula:C24H26N6Cor e Forma:SolidPeso molecular:398.50CDK2-IN-39
CAS:<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Fórmula:C14H15N3O4SCor e Forma:SolidPeso molecular:321.352CDK4/9-IN-1
CAS:<p>CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.</p>Fórmula:C22H34N6O2Cor e Forma:SolidPeso molecular:414.544P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49CTX-712
CAS:<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Fórmula:C19H17FN8O2Cor e Forma:SolidPeso molecular:408.39CDK7/12-IN-1
CAS:<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28CDK7-IN-17
CAS:<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Fórmula:C24H26F3N6OPCor e Forma:SolidPeso molecular:502.47CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Cor e Forma:SolidPeso molecular:359.355CDK7-IN-31
CAS:<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Fórmula:C27H32F5N6O2PCor e Forma:SolidPeso molecular:598.55Protein kinase inhibitor 11
CAS:<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Fórmula:C21H18FN5O2SCor e Forma:SolidPeso molecular:423.463Cdc7-IN-8
CAS:<p>Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK6-IN-1
CAS:<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Fórmula:C30H23N5Cor e Forma:SolidPeso molecular:453.54Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Fórmula:C14H14N4OSPureza:98.06%Cor e Forma:SolidPeso molecular:286.35YKL-1-116
CAS:<p>YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.</p>Fórmula:C34H38N8O3Pureza:98%Cor e Forma:SolidPeso molecular:606.72CDK9/PARP-IN-1
CAS:<p>CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.</p>Fórmula:C38H34F2N8O3Cor e Forma:SolidPeso molecular:688.725Protein kinase inhibitor 13
CAS:<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Fórmula:C19H20FN5OSCor e Forma:SolidPeso molecular:385.458Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK8-IN-5
CAS:<p>CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.</p>Fórmula:C26H22N2O4Cor e Forma:SolidPeso molecular:426.46CDK4/6-IN-3
CAS:<p>CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.</p>Fórmula:C25H31FN8Pureza:98%Cor e Forma:SolidPeso molecular:462.57SGC-CLK-1
CAS:<p>SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.</p>Fórmula:C19H15F3N6O2Cor e Forma:SolidPeso molecular:416.36p38α inhibitor 9
CAS:<p>p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.</p>Fórmula:C27H24FN3O3Cor e Forma:SolidPeso molecular:457.496GFB-12811
CAS:<p>GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.</p>Fórmula:C22H23F4N5OPureza:98.88%Cor e Forma:SolidPeso molecular:449.44LY3143921 hydrate
CAS:<p>LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].</p>Fórmula:C16H14FN5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:327.31Tanuxiciclib
CAS:<p>Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.</p>Fórmula:C15H13FN6OCor e Forma:SolidPeso molecular:312.308GSK-3/CDK5/CDK2-IN-1
CAS:<p>GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].</p>Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.433Tibremciclib
CAS:<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Fórmula:C28H32F2N8Pureza:98%Cor e Forma:SolidPeso molecular:518.6YK-2168
CAS:<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Fórmula:C16H18ClN5Cor e Forma:SolidPeso molecular:315.80Ref: TM-T200769
Produto descontinuado
